About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
SMART QUOTES
Smart
Quotes
Mankind Pharma Ltd.
Industry :
Pharmaceuticals & Drugs
BSE Code
543904
ISIN Demat
INE634S01028
Book Value
344.33
NSE Code
MANKIND
Dividend Yield %
0.00
Market Cap
1065545.93
P/E
54.44
EPS
47.44
Face Value
1
BSE
NSE
17-Apr-2025
BSE
NSE
NSE F & O
17-Apr-2025
BSE
NSE
NSE F & O
Last Price
2582.65
Net Change
60.2
% Change
2.39%
Prev.Close
2522.45
Open
2510.75
High
2600.00
Low
2505.00
Volume
19611
Last Price
2581.60
Net Change
61.6
% Change
2.44%
Prev.Close
2520.00
Open
2509.90
High
2600.00
Low
2500.00
Volume
489420
Value
50355235
Best Buy
0.00
Best Sell
0.00
Best Quantity
0
Sell Quantity
0
Today's Range
2600.00
52-Week High
3050.00
52-Week Low
1910.10
Value
1256173639.8
Best Buy
0.00
Best Sell
2581.60
Best Quantity
0
Sell Quantity
1
Today's Range
2600.00
52-Week High
3054.80
52-Week Low
1901.05
Open Price
High Price
Low Price
Last Price
Prev Close
Change
% Change
Average Price
Underlying Value
Number of contracts traded
Turnover in Rs. Lakhs
Open Interest
Change in O I
% Change in O I
%
Today
|
1W
|
1M
|
1Y
You need to upgrade your Flash Player
Best Bid
Best Offer
Quantity
0
Price
0.00
Quantity
0
Price
0.00
Best Bid
Best Offer
Quantity
0
Price
0.00
Quantity
1
Price
2581.60
Best Bid
Best Offer
Quantity
Price
Quantity
Price
Holding Details
More
Latest Corporate Events
Company News
15-04-2025
Mankind Pharma gets nod t...
03-04-2025
Mankind Pharma informs ab...
01-03-2025
Mankind Pharma informs ab...
10-02-2025
Mankind Pharma informs ab...
15-01-2025
Mankind Pharma informs ab...
27-12-2024
Mankind Pharma, Innovent ...
20-12-2024
Mankind Pharma informs ab...
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.